TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
SVA

Sinovac Biotech Ltd

Healthcare · Biotechnology

6.50$ +0.0% vs. previous close Closing price · As of: Sep 12, 2026

Ownership

Ownership Structure

Who owns Sinovac Biotech Ltd (SVA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 59.9% of the shares are freely tradable; institutional investors hold 32.0%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 32.0%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 51.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 59.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 99Mio.

Largest Shareholders

Institutions

Institutions SVA
Name Stake (%) Shares Change (%) Date
Vivo Capital, LLC 8.21 5,903,000 +0.0 06/30/2026
Orbimed Advisors LLC 3.78 2,718,735 +0.0 03/31/2026
Renaissance Technologies Corp 1.83 1,312,520 +0.0 03/31/2026
Neumann Advisory Hong Kong Ltd 0.44 315,586 +0.0 06/30/2026
Skandinaviska Enskilda Banken AB 0.11 80,000 +100.0 03/31/2026
California Public Employees Retrmnt Sys 0.10 68,732 +0.0 06/30/2026
Spark Investment Management LLC 0.04 29,100 +0.0 06/30/2026
Geode Capital Management, LLC 0.04 27,717 +0.0 03/31/2026
Susquehanna International Group, LLP 0.02 16,430 +0.0 03/31/2026

Funds

Funds SVA
Name Stake (%) Shares Change (%) Date
Fidelity Nasdaq Composite Index 0.04 27,717 +0.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?